Quantum Genomics

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Quantum Genomics had revenue of €10 and net profit of -€8.89M

(EUR)	2024	YoY
Revenue	10	99.95%
Gross profit	-1.15M	19.30%
Net profit	-8.89M	180.44%
EBITDA	-1.47M	53.01%

Fundamentals

Metric	Value
Market capitalization	€5M
Number of shares	69.34M
52-week high/low	€0.16 - €0.001
Dividends	No
Beta	0.16
P/E ratio	-0.55
PEG ratio	-0.01
P/B ratio	-2.05
P/S ratio	499,945.80

Company profile

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension; and in Phase IIb clinical trial for heart failure. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy; and QGC006 to optimize the treatment of hypertension with a monotherapy drug. The company was founded in 2005 and is based in Paris, France.